Rather, such deep immunological implications of senescence and OPN provide a stronger rationale for testing it in the subset of NSCLC candidate to treatments with immune checkpoint inhibitors [57, 58]. The gene discussed is SPP1; the disease is non-small cell lung carcinoma.